Solventum (SOLV) Raises Guidance After Q3 Beat, Is The Stock Still Undervalued?
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
Solventum (SOLV) just released third quarter 2026 results that combined a reported net loss with adjusted earnings per share beating expectations, while management lifted full year guidance and highlighted progress on major system transitions. Despite the earnings beat and
Directly affected
- SOLV Solventum-4.4% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Solventum belongs to, so it often moves with news about it.
- SYK Stryker+25.9% 30d
Stryker is a peer of Solventum in surgical and medical instruments and apparatus; rivals often move on the same news.
- MMM 3M+15.8% 30d
3M is a peer of Solventum in surgical and medical instruments and apparatus; rivals often move on the same news.
- BSX Boston Scientific+2.5% 30d
Boston Scientific is a peer of Solventum in surgical and medical instruments and apparatus; rivals often move on the same news.
- BDX Becton, Dickinson and+15.6% 30d
Becton, Dickinson and is a peer of Solventum in surgical and medical instruments and apparatus; rivals often move on the same news.
- MDLN Medline+10.4% 15d
Medline is a peer of Solventum in surgical and medical instruments and apparatus; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| SOLV | -6.61% | -2.71% | base | after close | after close | after close | after close |
| XLV | -0.05% | -0.52% | base | after close | after close | after close | after close |
| SYK | -13.02% | -7.34% | base | after close | after close | after close | after close |
| MMM | -7.16% | -5.69% | base | after close | after close | after close | after close |
| BSX | -5.94% | -2.51% | base | after close | after close | after close | after close |
| BDX | -7.32% | -7.14% | base | after close | after close | after close | after close |
| MDLN | -19.33% | -14.27% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Solventum (SOLV) Raises Guidance After Q3 Beat, Is The Stock Still Undervalued? Yahoo Finance Singapore
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| BDX | three days earlier | -7.14% | final price |
| BDX | five days earlier | -7.32% | final price |
| BSX | three days earlier | -2.51% | final price |
| BSX | five days earlier | -5.94% | final price |
| MDLN | three days earlier | -14.27% | final price |
| MDLN | five days earlier | -19.33% | final price |
| MMM | three days earlier | -5.69% | final price |
| MMM | five days earlier | -7.16% | final price |
| SOLV | three days earlier | -2.71% | final price |
| SOLV | five days earlier | -6.61% | final price |
| SYK | three days earlier | -7.34% | final price |
| SYK | five days earlier | -13.02% | final price |
| XLV | three days earlier | -0.52% | final price |
| XLV | five days earlier | -0.05% | final price |
Congressional trades in the stocks in this story
- Rep. Thomas H. Kean Jr sold Stryker (SYK), worth $1,001 - $15,000 on 30 Sep 2026. That is 37 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Stryker (SYK) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 42 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Stryker (SYK) (held by a dependent child), worth $15,001 - $50,000 on 11 Sep 2026. That is 56 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Kevin Hern sold Boston Scientific (BSX) (jointly held), worth $50,001 - $100,000 on 9 Sep 2026. That is 58 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Boston Scientific (BSX) (jointly held), worth $50,001 - $100,000 on 4 Sep 2026. That is 63 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Boston Scientific (BSX) (held by a dependent child), worth $1,001 - $15,000 on 3 Sep 2026. That is 64 days before publication. Filed 25 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
This story
12 out of 100
“Solventum (SOLV) Raises Guidance After Q3 Beat, Is The Stock Still Undervalued?” scores 12 out of 100. The score uses 1 sources.